Filing Flows › Companies › GoodRx Holdings › Analysis traps
GoodRx Holdings (GDRX): analysis traps
Where its figures could mislead a reader, and what to check before taking them at face value · Data: Q2 2026, to Jun 30, 2026, filed Aug 5, 2026; rules v1.1
GoodRx Holdings (GDRX): 1 rule of 10 triggered on the filings to Jun 30, 2026: adjusted profit = economic profit; 2 with insufficient data; 2 not applicable. Each is a question to verify, with the normal explanation that would produce the same figures.
Check these first
Adjusted profit = economic profit Triggered · severity high · confidence low
Adjusted EPS was at least 10% above GAAP in 3 of the last 3 quarters (on average 92% above). Costs excluded every quarter (restructuring, stock compensation, amortisation of acquired intangibles, litigation) are a recurring cost of the business, not a one-off.
Innocent reading: A genuine one-off this year (an impairment, a settlement) that happens to span several quarters.
Every rule
A01 FCF growth = the business improved Not triggered confidence high
Free cash flow did not rise ($183M → $164M): the trap does not arise.
The figures and how they are read
| Fiscal year before | FY2024 |
| Fiscal year | FY2025 |
| Operating cash flow, year before | $184M |
| Operating cash flow | $168M |
| Capex, year before | $1M |
| Capex | $4M |
| Free cash flow, year before | $183M |
| Free cash flow | $164M |
| Change in FCF | −$18M |
| Change in capex | $2M |
| Working capital: change in its cash contribution | −$97M |
FCF = operating cash flow − cash capex; ΔFCF = ΔOCF − ΔCapEx; the working-capital part is the change in the cash-bridge items (receivables, inventory, payables, accruals), with the sign of the cash flow statement
Source: FY2025 (cash flow statement, fiscal year) · FY2024 (cash flow statement, fiscal year before)
A07 Stock compensation added back = no economic cost Not triggered confidence high
Stock compensation is 9.6% of revenue, but buybacks of $216M covered it (2.8×) and the diluted share count fell 9.0%: the dilution has been paid for in cash.
The figures and how they are read
| Fiscal year | FY2025 |
| Stock compensation | $77M |
| Revenue | $797M |
| SBC / revenue | +9.6% |
| Buybacks | $216M |
| Buybacks / SBC | 2.8 |
| Diluted shares, year before | 392.2M shares |
| Diluted shares | 357.0M shares |
| Diluted shares: change | -9.0% |
SBC / revenue from the cash flow statement's add-back; the diluted weighted share count year over year; buybacks from the financing section
Source: FY2025 (stock compensation, buybacks and the diluted share count, fiscal year)
B02 Receivables growing = future cash is certain Not triggered confidence medium
Receivables grew -4% against revenue -1% in Q2 2026; DSO 94 against a median of 78: collections are keeping pace with sales.
The figures and how they are read
| Quarter | Q2 2026 |
| Revenue, year over year | -1.3% |
| Receivables, year over year | -3.6% |
| Quarter before | Q1 2026 |
| Revenue y/y, quarter before | -4.4% |
| Receivables y/y, quarter before | +45.3% |
| Days sales outstanding | 94.2 |
| DSO, median of eight quarters | 78.2 |
| Receivables | $182M |
| Revenue | $200M |
receivables and revenue against the same quarter a year earlier; DSO = receivables / quarterly revenue × days, against the median of the eight quarters before
Source: Q2 2026 (receivables and revenue) · Q2 2025 (the same quarter a year earlier)
B08 Adjusted profit = economic profit Triggered severity high · confidence low
Adjusted EPS was at least 10% above GAAP in 3 of the last 3 quarters (on average 92% above). Costs excluded every quarter (restructuring, stock compensation, amortisation of acquired intangibles, litigation) are a recurring cost of the business, not a one-off.
The figures and how they are read
| Quarter / adjusted EPS / GAAP EPS / gap | 2025-09-30 / 0.08 / 0.0 / 1.0; 2026-03-31 / 0.07 / 0.0 / 1.0; 2026-06-30 / 0.08 / 0.02 / 0.75 |
| Quarters with adjusted ≥ 10% above GAAP | 3 |
| Quarters compared | 3 |
| Latest gap | +75.0% |
the analysts' 'actual' (usually the company's adjusted EPS) against GAAP net income ÷ diluted shares for the matching quarter; a gap of 10% or more counts (the stand-in until three releases' reconciliation tables are on file)
Source: 2025-09-30 (adjusted 0.08 vs GAAP 0.00) · 2026-03-31 (adjusted 0.07 vs GAAP 0.00) · 2026-06-30 (adjusted 0.08 vs GAAP 0.02)
What would explain it innocently
- A genuine one-off this year (an impairment, a settlement) that happens to span several quarters
- Amortisation of acquired intangibles, which many investors also exclude by choice
- The analysts' 'actual' is not the company's own adjusted figure
What to look for in the filing
- The reconciliation table in the earnings release: which items, how much, how often
- Whether the same items were excluded in earlier years
What would show the trap does not apply
- The reconciliation shows the excluded items ending (a restructuring with its final charge, a settlement paid) and the gap to GAAP closes in the next quarters
- The excluded items are only amortisation of acquired intangibles and the cash paid for the deals is in the investing cash flow
Look again: next filing.
C02 Low net debt = no refinancing risk Not triggered confidence medium
$5M comes due within a year, 98.6× covered by cash and investments of $296M plus $197M of free cash flow.
The figures and how they are read
| Cash and investments | $296M |
| Debt | $495M |
| Net debt | $199M |
| Due within a year | $5M |
| Read from | the debt maturity table |
| Free cash flow, twelve months | $197M |
| Cash plus free cash flow | $493M |
| Coverage of what is due | 98.6 |
| Due in the second year | $5M |
| Balance sheet date | 2026-06-30 |
due within a year from the maturity table (else the current portion of debt), against cash and investments plus free cash flow over the last twelve months (zero if negative); no credit lines assumed
Source: FY2025 (debt maturities, cash and investments)
D03 EPS growth = profit growth Not triggered confidence high
EPS fell 31% and net income fell 34% in Q2 2026; the share count fell 2.5%: EPS growth follows profit growth.
The figures and how they are read
| Quarter | Q2 2026 |
| Quarter before | Q2 2025 |
| EPS, year before | $0.04 |
| EPS | $0.03 |
| Net income, year before | $13M |
| Net income | $9M |
| Diluted shares, year before | 357.2M shares |
| Diluted shares | 348.1M shares |
| EPS growth | -30.6% |
| Net income growth | -33.5% |
| Diluted shares: change | -2.5% |
| eps from profit | -$0.01 |
| eps from share count | $0.00 |
EPS and net income against the same quarter a year earlier; the EPS bridge attributes the change to profit first, then to the share count (the order is fixed and disclosed)
Source: Q2 2026 (net income, diluted shares, EPS) · Q2 2025 (the same quarter a year earlier)
E02 Low P/E at a cyclical peak = undervalued Insufficient data
no market value or trailing net income in the valuation research
E07 A precise DCF value = the true value Insufficient data
no DCF in the valuation research for this company
J06 A bank's low P/E and high profit = safe Not applicable
not a bank
J08 A REIT's low net income = the dividend is unsafe Not applicable
not a REIT
What the statuses mean
Triggered: the filings show the pattern; read the normal explanations and the missing evidence before concluding anything. To review: one quarter or a weak signal; a reader's judgement, not a pattern. Not triggered: the pattern is absent on these figures. Insufficient data: the filings read so far do not hold what the rule needs; this is not a clean bill. Not applicable: the rule is not meant for this kind of company (a bank's working capital, a loss-making quarter's EPS growth). Out of date: the latest filing is more than fifteen months old.
Severity is what the pattern could mean for cash, value or solvency; confidence is how reliable the inputs and the reading are. The two are kept apart.
Record a view
A reader's judgement, grounds, what would change it and the next review; kept in the browser (needs JavaScript).
Every rule and the companies it triggers on → GoodRx Holdings: cash flow →
Each rule reads the company's own filings by a fixed formula and says what would explain the same figures innocently. A triggered rule is a question to verify, not a finding of manipulation, and not a view on the stock. Missing data is shown as missing, never as clear. Not investment advice.